|1.||Incardona, Josephine: 1 article (09/2009)|
|2.||Cheng, Hsien C: 1 article (09/2009)|
|3.||Wang, Y-J: 1 article (09/2008)|
|4.||Lin, A-A: 1 article (09/2008)|
|5.||Lin, M-W: 1 article (09/2008)|
|6.||Wu, S-N: 1 article (09/2008)|
|7.||Peng, H: 1 article (09/2008)|
|8.||Reynolds, William P: 1 article (12/2007)|
|9.||Rampe, David: 1 article (12/2007)|
|10.||Kang, Jiesheng: 1 article (12/2007)|
12/01/1987 - "DPI 201-106 produced hemodynamic improvement in patients with severe congestive heart failure."
09/01/1989 - "1. The present study was designed to characterize the positive inotropic response to DPI 201-106 in isolated papillary muscle strips obtained from heart failure patients undergoing surgery. "
05/01/1988 - "Having demonstrated beneficial, acute haemodynamic effects in this study, further work should be undertaken with DPI 201-106 to investigate the effect of chronic treatment in patients with cardiac failure."
08/01/1996 - "A gas chromatographic/mass spectrometric procedure using single-ion monitoring and repetitive scanning was developed to characterize and determine methyl methanesulphonate (MMS) and ethyl methanesulphonate (EMS) in the free base and bismesylate salt of DPI 201-106, a positive inotropic agent used in the treatment of heart failure. "
08/01/1996 - "Gas chromatographic/mass spectrometric analysis of methyl methanesulphonate and ethyl methanesulphonate in the bismesylate salt of DPI 201-106, a positive inotropic agent for the treatment of heart failure."
|2.||Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
07/01/1986 - "DPI 201-106 (DPI) as a positive inotropic drug might be useful in treating dilated cardiomyopathy (DCM). "
07/01/1986 - "Comparative efficacy of the new cardiotonic agent DPI 201-106 versus dobutamine in dilated cardiomyopathy: analysis by serial pressure/volume relations and "on-line" MVO2 assessment."
|3.||Torsades de Pointes (Torsade de Pointes)
07/01/2003 - "Acute administration of DPI 201-106 prolonged the QT interval, provoked spontaneous torsades de pointes in one patient, and facilitated stimulation-induced polymorphic ventricular tachyarrhythmias in two patients. "
09/01/2009 - "Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts."
04/01/1988 - "Thus, Ca2+ antagonism contributes to the complex pharmacologic profile of DPI 201-106, and is probably responsible for the bradycardia and lowering of systemic vascular resistance observed in vivo."
08/01/1998 - "Bradycardia was induced by dissection of the sinus node, and prolongation of the QT interval by infusion of two inhibitors of the sodium channel inactivation, veratridine and DPI 201-106. "
03/01/1999 - "Na+and Ca2+overload-associated arrhythmias can be produced experimentally by inhibition of Na+efflux (digitalis-induced intoxication) and by abnormal Na+influx via modulated Na+channels (veratridine, DPI 201-106; hypoxia) or via the Na+, H+exchanger. "
01/01/1987 - "When DPI 201-106, a cardiotonic agent, was given to the hypoxia moded by increasing the Ca++ sensitivity of contractile proteins, further increases were observed in LVEDP (to 25 +/- 8 mmHg, p less than 0.05) and Po (to 15 +/- 7 mmHg, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)"
|5.||Sodium Channels (Sodium Channel)
|6.||Ouabain (G Strophanthin)
|8.||6- cyano- 4- (N- ethylsulfonyl- N- methylamino)- 3- hydroxy- 2,2- dimethylchromane